A year ago, the Swiss Academy of Medical Sciences organized a symposium on drug problems, and the proceedings have recently been published in booklet form. During the months that have passed since the symposium was held, the significance of the topics discussed has not diminished, and most of what was said during the meeting is as valid today as it was at the time of presentation. The Swiss pharmaceutical industry comprises some of the most important drug producers in the world, and it is therefore of great interest to learn how drug control and the various aspects of evaluation and surveillance of drugs are operated in Switzerland. Various Swiss experts working in university departments, for the drug regulatory agency, and in industry have contributed to the proceedings; their papers give a good illustration of the way in which a small country with limited administrative means can establish effective drug control. It is evident that good cooperation between the various parties involved in the development of drugs is more helpful in establishing the efficacy and safety of drugs than far-reaching and restrictive regulations. In this respect the symposium was revealing, and a study of the proceedings is especially recommended to all persons responsible for drug control in countries where there is a discrepancy between the capacity of the pharmaceutical industry and the government institutions charged with the approval of new drugs.
F. Gross
C O R R E S P O N D E N C E
Dr. A. W. Peck, co-author of the paper on "Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts", which appeared in the Europ. J. clin. Pharmac. 6, 170-176, 1973 , informed us that he and his associates had only recently become aware of the fact that Drs K. G. G6testam and L. M. Gunne had published in detail, in the Brit. J. of Addiction 67, [39] [40] [41] [42] [43] [44] 1972 , data that had before been presented in abstract form only. Dr. Peck regrets the oversight and draws attention to the above-mentioned publication on clinical evaluation of central stimulant effects of fenfluramine and AN 448.
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